Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05609331 · ClinicalTrials.gov registry record · NA
Feasibility, Safety, and Efficacy of Stereotactic MRI-Guided Adaptive Radiation Therapy (SMART) for Central Lung Tumors
A NA study, sponsored by M.D. Anderson Cancer Center.
- Terminated
- Registry status
- NA
- Development phase
- 3
- Enrollment target
NCT05609331: Clinical Trial NA study, sponsored by M.D. Anderson Cancer Center.
NCT05609331 is a NA study that was terminated before completion, run by M.D. Anderson Cancer Center. The registered enrollment target is 3 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05609331, a NA study, was terminated before completion, sponsored by M.D. Anderson Cancer Center.
- TERMINATED
- Registry status
- NA
- Development phase
- 3 participants
- Enrollment target
Study Summary
To learn if using MRI (magnetic resonance imaging) to guide radiation therapy can help to control central lung cancer. The results of the MRI-guided radiation therapy will be compared to conventional radiation therapy (guided by CT scans) during this study.
Interventions
- OTHER Simulated Online Adaptive Planning
- RADIATION Stereotactic MRI-guided adaptive radiotherapy-SMART
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2022-11-17 |
| Est. Completion | 2025-11-05 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05609331
The ClinicalTrials.gov registry entry for NCT05609331 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Simulated Online Adaptive Planning is the first listed.
NCT05609331 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05609331 about?
NCT05609331 is a clinical study titled "Feasibility, Safety, and Efficacy of Stereotactic MRI-Guided Adaptive Radiation Therapy (SMART) for Central Lung Tumors". To learn if using MRI (magnetic resonance imaging) to guide radiation therapy can help to control central lung cancer. The results of the MRI-guided radiation therapy will be compared to conventional radiation therapy (guided by CT scans) during this study.
What is the current status of trial NCT05609331?
This trial is currently terminated. It is a NA study. The enrollment target is 3 participants. The study started on 2022-11-17. Estimated completion is 2025-11-05.
What interventions are being tested in trial NCT05609331?
The interventions under investigation include: Simulated Online Adaptive Planning (OTHER), Stereotactic MRI-guided adaptive radiotherapy-SMART (RADIATION).
Who is sponsoring clinical trial NCT05609331?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.